Curcumin, a dietary phytochemical, exhibits multifunctional natural product with regulatory effects on inflammation. However, the poor bioavailability limits its clinical applications. Thus, we designed and synthesized a novel monocarbonyl analogue of curcumin B7 and their inhibition against monocyte chemotactic protein-1 (MCP-1) and interleukin-8(IL-8) release was evaluated in H 2O2-stimulated human vascular endothelial cells (ECs) in a dose-responsive manner, while exhibiting no cytotoxicity in ECs. Taken together, these insights on the novel compound B7 may serve as potential agents for the treatment of atherosclerosis.